Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.41 |
| ▸ | CD44 | P16070 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986870 | 0.86 | HTR2C (0.41) | PNMTCD44MAOBHTR2CCHRNB2 | |
| SCHEMBL611712 | 0.85 | PNMT (0.41) | PNMTCD44MAOBHTR2CADRA2A | |
| SCHEMBL337488 | 0.78 | PNMT (0.34) | PNMTCD44MAOBADRA2AADRA2B | |
| SCHEMBL156197 | 0.71 | ADRA2A (0.35) | HTR2CADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL17986607 | 0.69 | ADRA2A (0.34) | HTR2CADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL338410 | 0.69 | ADRA2A (0.34) | HTR2CADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL10272539 | 0.69 | HTR2C (0.45) | PNMTCD44MAOBHTR2CADRA2A | |
| SCHEMBL1593106 | 0.69 | HTR2C (0.41) | PNMTCD44MAOBHTR2CADRA2A | |
| SCHEMBL4440094 | 0.68 | CYP3A4 (0.43) | PNMTCD44MAOBHTR2CADRA2A | |
| SCHEMBL4341019 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024118926-A1 | 4-(3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)-PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF THE KRAS(G12D) MUTANT ONCOPROTEIN FOR THE TREATMENT OF CANCER | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2024-06-06 | — | — | WO | claimed |
| CN-117157299-B | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| US-20240158414-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2024-05-16 | — | — | US | claimed |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-02 | — | — | US | claimed |
| US-20240082223-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-14 | — | — | US | claimed |
| CN-117624169-A | 5-HT of the type 2A Receptor agonist, preparation method and application thereof | 上海翊石医药科技有限公司 | 2024-03-01 | — | — | CN | claimed |
| EP-4041714-B1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-12-13 | — | — | EP | claimed |
| CN-117157299-A | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2023-12-01 | — | — | CN | claimed |
| CN-117069720-A | 5-HT 2A Receptor agonist, preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-11-17 | — | — | CN | claimed |
| EP-4263547-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-10-25 | — | — | EP | claimed |
| EP-4041714-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-08-17 | — | — | EP | claimed |
| WO-2022128853-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-23 | — | — | WO | claimed |
| CN-114630822-A | Biaryl dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-06-14 | — | — | CN | claimed |
| CN-114599652-A | Hydropyrazino [1,2-d ] [1,4] diazepin compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-06-07 | — | — | CN | claimed |
| US-20210300947-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-09-30 | — | — | US | claimed |
| EP-3807270-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-04-21 | — | — | EP | claimed |
| WO-2021070132-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2021-04-15 | — | — | WO | claimed |
| CN-112313228-A | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-02-02 | — | — | CN | claimed |
| WO-2019238616-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-19 | — | — | WO | claimed |
| WO-2019141096-A1 | SUBSTITUTED UREA COMPOUND AND PREPARATION METHOD AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2019-07-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300947-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, UACA, HLA-DRB1 | PNMT 4607/4885CD44 3334/4885MAOB 2782/4885 |
| US-20240082223-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | PNMT 2935/4885CD44 4772/4885MAOB 539/4885 |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP11B2, SDHA, CYP3A43 | PNMT 2408/4885CD44 2825/4885MAOB 68/4885 |
| US-20240158414-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | PNMT 3314/4885CD44 4478/4885MAOB 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.